

HCV Peptide (35-44)

Cat. No.:	HY-P4032
CAS No.:	160214-01-7
Molecular Formula:	C ₅₇ H ₉₇ N ₁₉ O ₁₂
Molecular Weight:	1240.5
Sequence Shortening:	YLLPRRGPRRL
Target:	HCV
Pathway:	Anti-infection
Storage:	Sealed storage, away from moisture and light, under nitrogen
	Powder -80°C 2 years
	-20°C 1 year

YLLPRRGPRRL

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro

H₂O : 100 mg/mL (80.61 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		0.8061 mL	4.0306 mL	8.0613 mL
	5 mM		0.1612 mL	0.8061 mL	1.6123 mL
	10 mM		0.0806 mL	0.4031 mL	0.8061 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor [1].

In Vitro

HCV Peptide (35-44) (0-100 µM) inhibits degranulation of the total NK cell population. HCV Peptide (35-44) increases cell surface expression of both HLA-C and HLA-E^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Cheent KS, et, al. P91 Dual mechanism of NK cell inhibition by the HCV core 35–44 peptide. BMJ journals. 60(Sup 2).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA